use
total
serum
sampl
studi
tabl
appendix
sampl
repres
patient
serolog
identifi
pcrconfirm
merscov
infect
cohort
healthi
blood
donor
control
group
patient
confirm
rtpcr
respiratori
viru
infect
assess
assay
specif
use
serum
sampl
netherland
approv
erasmu
medic
center
local
medic
ethic
committe
mec
approv
institut
ethic
review
board
seoul
nation
univers
hospit
approv
use
sampl
patient
south
korea
approv
ethic
institut
anim
care
use
committe
medic
research
center
hamad
medic
corpor
approv
use
sampl
qatar
permit
test
serum
sampl
merscov
neutral
antibodi
use
plaqu
reduct
neutral
assay
prnt
reactiv
use
routin
elisa
relisa
euroimmun
http
wwweuroimmuncom
inhous
elisa
ielisa
protein
microarray
nucleocapsid
reactiv
use
luciferas
immunoprecipit
assay
nlip
reactiv
use
elisa
appendix
evalu
specif
sensit
predict
valu
assay
platform
use
serum
sampl
patient
pcrdiagnos
merscov
infect
respiratori
patient
healthi
control
compar
perform
assay
platform
pcr
perform
use
fisher
exact
test
use
receiv
oper
characterist
roc
curv
compar
perform
differ
platform
perform
statist
analys
use
graphpad
prism
version
http
wwwgraphpadcom
sever
studi
propos
antibodi
level
longev
follow
merscov
infect
depend
diseas
sever
among
pcrconfirm
mer
patient
mild
infect
may
result
undetect
lower
shortliv
immun
respons
compar
sever
infect
evalu
antibodi
respons
sever
mild
merscov
infect
use
serum
sampl
collect
month
diseas
onset
pcrconfirm
merscov
patient
south
korea
outbreak
sever
mild
infect
first
test
serum
sampl
merscov
antibodi
use
differ
assay
platform
figur
appendix
tabl
consist
earlier
report
routin
use
relisa
detect
mild
infect
figur
panel
contrast
ielisa
detect
mild
infect
figur
panel
b
similar
result
obtain
use
protein
microarray
screen
antibodi
figur
panel
c
although
serum
sampl
lack
merscov
neutral
antibodi
presenc
nucleocapsid
antibodi
year
postinfect
mildli
infect
patient
sampl
confirm
result
elisa
assay
target
anoth
merscov
protein
figur
panel
sever
case
hand
found
posit
test
platform
year
diseas
onset
indic
robust
immun
respons
high
antibodi
titer
sever
case
figur
appendix
tabl
compar
milder
infect
neutral
antibodi
respons
higher
sever
infect
case
confirm
antibodi
respons
lower
follow
nonsever
infect
confirm
variat
detect
mild
case
caus
sensit
differ
platform
use
valid
platform
specif
sensit
use
serum
sampl
tabl
use
merscov
neutral
standard
merscov
serolog
test
serum
sampl
use
plaqu
reduct
neutral
assay
nucleocapsid
reactiv
assess
specif
assay
use
serum
sampl
cohort
healthi
blood
donor
cohort
patient
pcrconfirm
acut
respiratori
noncov
infect
cohort
b
patient
acut
convalesc
pcrconfirm
infect
cohort
c
none
serum
sampl
specif
cohort
reactiv
ielisa
set
cutoff
indic
specif
figur
panel
appendix
also
evalu
sensit
detect
merscov
infect
ielisa
abl
detect
merscov
infect
among
person
camel
contact
cohort
low
antibodi
level
determin
protein
microarray
use
sampl
acutephas
pcrdiagnos
patient
cohort
e
detect
seroposit
day
postdiagnosi
dpd
convalescentphas
serum
sampl
cohort
f
posit
last
time
point
test
dpd
patient
dpd
patient
appendix
figur
result
reveal
high
specif
sensit
elisa
platform
support
earlier
find
confirm
sensit
platform
detect
low
immun
respons
among
case
milder
infect
cohort
g
figur
overal
ielisa
ci
specif
ci
sensit
detect
pcrconfirm
case
overal
test
cohort
ci
tabl
moreov
ielisa
perform
accord
merscov
protein
microarray
figur
panel
b
microarray
valid
show
pattern
specif
fals
posit
specif
ci
cohort
sensit
ci
pcrconfirm
case
overal
ci
specif
antigen
merscov
serolog
support
rate
seroposit
serum
sampl
cohort
determin
microarray
figur
panel
c
sampl
seroneg
sarscov
merscov
fals
posit
detect
ielisa
microarray
overal
result
provid
evid
use
specif
antigen
merscov
serolog
evalu
nucleocapsid
antibodi
respons
merscov
infect
set
cutoff
none
control
serum
sampl
test
posit
nucleocapsid
antibodi
figur
panel
detect
seroconvers
nucleocapsidluciferas
immunoprecipit
assay
among
sever
infect
mildli
infect
asymptomat
person
camel
contact
test
merscov
antibodi
respons
none
control
serum
sampl
cohort
crossreact
figur
panel
e
wherea
sampl
sampl
person
camel
contact
test
posit
find
indic
low
immun
respons
mild
mer
case
thu
compar
use
n
protein
detect
merscov
infect
show
highest
specif
sensit
among
test
protein
strikingli
routin
use
elisa
show
least
sensit
among
test
platform
tabl
figur
figur
panel
f
saw
differ
cohort
person
camel
contact
qatar
mild
asymptomat
infect
identifi
seroposit
merscov
earlier
studi
figur
panel
f
cohort
although
test
seroposit
ielisa
microarray
platform
also
test
posit
use
relisa
platform
test
differ
coat
condit
found
reduct
antigen
coat
loss
conform
epitop
could
contribut
low
sensit
seen
relisa
versu
ielisa
despit
test
antigen
figur
low
sensit
confirm
likelihood
falseneg
detect
merscov
case
use
relisa
evalu
specif
relisa
platform
use
cohort
among
serum
sampl
patient
infect
test
posit
figur
panel
f
test
neg
merscov
neutral
antibodi
ielisa
microarray
tabl
thu
confirm
crossreact
serum
sampl
merscov
relisa
test
serum
sampl
taken
patient
differ
time
point
infect
preinfect
serum
sampl
neg
postinfect
serum
sampl
posit
relisa
figur
contrari
none
serum
sampl
posit
test
prnt
western
blot
immunofluoresc
assay
ielisa
protein
microarray
use
commerci
inhous
protein
indic
falseposit
reaction
relisa
overal
relisa
ci
specif
test
cohort
tabl
use
lower
cutoff
optic
densiti
ratio
show
specif
sensit
suggest
earlier
studi
increas
sensit
reduc
specif
number
falseposit
result
increas
specif
decreas
appendix
figur
investig
differ
neutral
respons
produc
follow
sever
mild
infect
reliabl
neutral
assay
confirmatori
assay
mild
infect
valid
specif
sensit
detect
merscov
infect
although
none
healthi
blood
donor
cohort
reactiv
respiratori
patient
cohort
b
c
show
low
level
crossneutr
titer
serum
sampl
one
sampl
titer
figur
panel
g
patient
none
serum
sampl
taken
earlier
time
point
patient
show
neutral
prnt
data
shown
serum
sampl
test
neg
antibodi
test
platform
tabl
none
serum
sampl
posit
assay
pcrdiagnos
mer
case
cohort
show
sensit
detect
sever
case
seroconvers
period
dpd
cohort
f
year
cohort
h
indic
strong
neutral
antibodi
respons
contrast
result
vari
mild
case
cohort
g
neutral
antibodi
detect
mild
infect
appendix
tabl
highlight
lower
shorterliv
neutral
respons
among
mild
case
find
consist
result
cohort
mild
asymptomat
person
camel
contact
qatar
figur
panel
g
cohort
person
low
undetect
neutral
antibodi
reactiv
protein
microarray
platform
ielisa
pcrconfirm
merscov
patient
cohort
serolog
posit
person
camel
contact
cohort
antibodi
titer
determin
ielisa
strongli
correl
neutral
titer
figur
panel
show
antibodi
respons
reliabl
predictor
neutral
activ
find
indic
popul
mildli
infect
patient
antibodi
detect
neutral
antibodi
could
easili
miss
attempt
confirm
case
neutral
assay
serolog
detect
merscov
exposur
valuabl
identifi
asymptomat
case
viru
reservoir
popul
screen
epidemiolog
studi
well
contact
investig
detect
aid
understand
host
immun
respons
viru
identifi
key
viral
immunogen
map
key
neutral
antibodi
lead
implement
appropri
prevent
therapeut
measur
antibodi
respons
vari
among
pcrconfirm
merscov
case
casepati
mild
asymptomat
infect
show
low
undetect
seroconvers
contrast
sever
infect
result
robust
respons
lowlevel
antibodi
respons
produc
follow
nonsever
infect
led
failur
detect
respons
patient
routin
use
elisa
neutral
assay
result
may
imped
estim
preval
viru
infect
surveil
studi
abl
detect
nonneutr
antibodi
respons
among
previous
infect
mild
asymptomat
case
previous
unidentifi
find
indic
merscov
preval
could
higher
current
estim
use
sensit
platform
could
lead
precis
calcul
incid
rate
although
earlier
studi
evalu
serolog
respons
among
pcrconfirm
mer
patient
report
seroconvers
mildli
infect
case
abl
detect
inhous
elisa
microarray
ielisa
microarray
highli
sensit
detect
merscov
infect
show
specif
test
cohort
although
relisa
platform
detect
sever
infect
fals
neg
detect
seroconvers
among
mildli
infect
pcrconfirm
asymptomat
person
camel
contact
low
antibodi
respons
addit
relisa
result
show
crossreact
serum
sampl
person
variat
reactiv
elisa
platform
could
attribut
differ
coat
protein
prepar
use
reduc
stabil
protein
storag
relisa
platform
overal
result
valid
use
specif
antigen
merscov
serolog
fold
correct
provid
highli
specif
diagnost
approach
without
fals
posit
omit
need
confirmatori
assay
particular
neutral
antibodi
undetect
asymptomat
mild
infect
use
instead
reduct
cutoff
prnt
increas
sensit
assay
confirm
mild
asymptomat
infect
crucial
preced
prnt
sensit
screen
assay
avoid
falseneg
result
prolong
viral
shed
observ
sever
infect
patient
patient
mild
infect
indic
shortliv
infect
nonsever
case
may
account
lower
antibodi
respons
includ
function
neutral
antibodi
possibl
reason
nonneutr
antibodi
compris
substanti
proport
antibodi
elicit
viral
infect
antibodi
elicit
viral
protein
includ
immatur
form
surfac
protein
releas
lysi
infect
cell
follow
shortliv
abort
infect
found
spike
antibodi
titer
produc
higher
titer
nucleocapsid
antibodi
neutral
antibodi
undetect
follow
nonsever
infect
find
indic
antispik
antibodi
sensit
predictor
previou
merscov
infect
especi
mild
asymptomat
infect
conduct
neutral
assay
confirm
serolog
find
recommend
world
health
organ
could
result
potenti
underestim
true
preval
epidemiolog
studi
studi
test
patient
previous
indetermin
infect
could
provid
clue
epidemiolog
merscov
recent
studi
report
presenc
tcell
respons
merscov
infect
irrespect
diseas
sever
therefor
tcell
assay
use
confirm
serolog
find
epidemiolog
studi
mainli
asymptomat
case
instead
neutral
assay
could
yield
underestim
result
howev
studi
need
rule
possibl
tcell
crossreact
hcov
despit
use
reduct
endpoint
prnt
observ
crossneutr
respiratori
panel
sampl
sampl
titer
report
similar
find
earlier
studi
neg
serum
sampl
neutral
titer
find
unexpect
neutral
assay
high
specif
consid
standard
merscov
serodiagnosi
seemingli
fals
posit
could
attribut
presenc
natur
antibodi
crossreact
hcov
antibodi
crossneutr
among
human
coronavirus
rare
report
chan
et
al
describ
crossneutr
sarscov
merscov
low
titer
howev
serum
sampl
also
test
posit
neutral
find
along
rais
probabl
antibodi
caus
crossreact
antibodi
serum
sampl
could
recogn
epitop
outsid
thu
detect
elisa
interest
detect
patient
serum
sampl
could
neutral
merscov
titer
found
patient
receiv
oncolyt
medic
shown
antivir
activ
find
could
also
probabl
reason
observ
crossneutr
overal
serum
sampl
healthi
blood
donor
show
crossneutr
crossreact
n
protein
observ
crossneutr
compar
higher
reactiv
n
protein
serum
sampl
patient
respiratori
infect
detect
inhous
platform
thu
could
avoid
crossreact
n
protein
lead
fals
posit
without
loss
sensit
high
specif
protein
enabl
us
set
cutoff
high
enough
ensur
specif
without
lose
sensit
use
optim
platform
enabl
us
detect
seroconvers
among
otherwis
unrecogn
nonsever
merscov
case
high
sensit
specif
find
indic
ielisa
microarray
merscov
diagnost
tabl
figur
panel
b
could
reliabl
diagnost
tool
identifi
merscov
infect
standard
assay
calibr
eg
monoclon
antibodi
includ
run
avoid
intraassay
variat
although
test
larger
cohort
may
requir
rule
crossreact
ensur
sensit
therebi
valid
gener
use
diagnost
assay
data
obtain
studi
indic
crossreact
hcov
least
test
merscov
sarscov
reactiv
unlik
occur
use
optim
platform
diverg
protein
recent
followup
studi
reveal
among
serum
sampl
test
use
inhous
elisa
includ
person
camel
contact
sampl
posit
test
posit
wherea
serum
sampl
found
neg
ielisa
r
bassal
et
al
unpub
data
thu
principl
lowlevel
antibodi
respons
among
nonsever
merscov
case
may
reveal
singl
elisa
test
patient
mild
asymptomat
infect
develop
sever
ill
thu
go
unrecogn
might
play
role
spread
viru
commun
initi
outbreak
index
casepati
report
histori
camel
patient
exposur
therefor
defin
subclin
burden
infect
enabl
better
understand
extent
sever
public
health
threat
pose
merscov
turn
guid
develop
implement
proper
strategi
contain
prevent
ongo
outbreak
infect
viru
